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Abstract  
 
Objectives. To explore the change in direct medical costs associated with inflammatory 
polyarthritis (IP) 10 to 15 years after its onset.  
 
Methods.  Patients from the Norfolk Arthritis Register (NOAR) who had previously 
participated in a health economic study in 1999 were traced ten years later and invited 
to participate in a further prospective questionnaire-based study.  The study was 
designed to capture direct medical costs and changes in health status over a 6-month 
period, using previously validated questionnaires as the primary source of data. 
 
Results. A representative sample of 101 patients with IP from the 1999 cohort provided 
complete data over the 6-month period. The mean disease duration was 14 years (SD 
2.1, median 13.6, IQR 12.6-15.4).  The mean direct medical cost per patient over the 6-
month period was: £1496 for IP (inflated for 2013 prices). This compared with £582 
(95% CI £355-£964) inflated to 2013 prices per patient with IP ten years earlier in their 
disease. The increased cost was largely associated with use of biologics in the RA sub-
group of patients (51% of total costs incurred).  Other direct cost components included 
primary care costs 11%; hospital outpatient 19%; day care 12%; inpatient stay 4%. 
 
Conclusions. The direct health care costs associated with IP have more than doubled 
with increasing disease duration, largely as a result of the use of biologics.  The results 
showed a shift in the direct health costs from inpatient to outpatient service use.  
 
 
 
 
 
 
 
Introduction 
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Inflammatory arthritis (IP), of which rheumatoid arthritis (RA) is a subset, is a chronic 
and disabling condition with a lifelong course and considerable economic impact both 
on the affected individual and on society.[1]  In 1992, the annual costs of RA in 
England were estimated to be £1.26 billion [2] with the direct costs (the use of primary 
and secondary care services and drug costs) accounting for 48% of the total, the 
remainder reflecting indirect health costs.   Almost 20 years later, the estimated cost of 
RA in England has risen to approximately £8 billion a year (DH drug costs 2011).[3]  
 
Establishing the true cost associated with IP is complex because costs change over the 
time course of the disease with age, disease progression and changing treatment 
strategies. Secular changes in disease severity, the earlier introduction of disease 
modifying agents and the use of targeted management regimes together with the 
increasing availability of biologic agents, are all likely to have complex and competing 
effects on long term costs.[4] 
 
In 1999, as part of a wider assessment of the costs of new-onset IP, we examined the 
costs of disease using a cohort of 133 consecutive patients from the Norfolk Arthritis 
Register (NOAR), recruited between 1994 and 1999.[5]  A total 50% subsequently 
developed RA.  An analysis of the data obtained using a validated resource use and 
expenditure questionnaire [5,6] revealed that, in the first five years after disease onset, 
direct health costs represented 14% of the total, the main component being in-patient 
and day care stays (33%).  This was followed by prescribed medication, which 
accounted for 30% of the total health service costs.   
 
In this follow up cross-sectional study we re-evaluate the cost of the disease after a 
further 10 years in a sample taken from the same cohort of patients.  This community 
based longitudinal cohort design provides a unique opportunity to observe the changing 
costs of treatment associated with IP and its progression against a changing therapeutic 
backdrop.  
 
 
 
Methods 
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Study subjects 
NOAR is a long-term prospective cohort of over 4,000 patients with new onset IP (>2 
swollen joints lasting >4 weeks) identified from primary care and hospital sources 
within the boundaries of the former Norwich Health Authority UK, starting in 1990 and 
currently on-going.[7,8]    
 
In 1999 a health economic evaluation was conducted prospectively over a 6-month 
period among 133 patients with IP in the community, using self-completion postal 
questionnaires, designed and validated for the study.[5] These questionnaires (available 
as supplementary material) included detailed sections on primary care and hospital 
visits (to see doctors, nurses or other health care professionals),  prescribed medications 
and over-the-counter drugs.  An extra question was added to the original questionnaires 
under the medications section, to capture the use of biologic DMARDs in the current 
study. Any reporting of biologic DMARD use was checked against the patients’ paper 
records to ensure accurate recording of information. Questions on medications included 
the type of drugs used, dosage, number of prescriptions and duration of treatment, 
enabling the calculation of costs using standard UK prices (see below) at individual 
patient level. A second cross-sectional study, which also took place in 1999, recruited 
218 NOAR participants. Both studies in 1999 were designed to estimate the health 
service (direct health costs), non-health service (e.g. over the counter medications) and 
total costs of early IP.[5]   The subjects recruited were consecutive patients entering 
NOAR between 1994-1999.  When interviewed by the NOAR research nurses at the 
time of recruitment, 267 patients had given permission for further contact by the register 
and could be located in 2009.  The remaining patients had either died, declined NOAR 
in the intervening period, were untraceable or had pre-arranged agreement with the 
study team in 1999 not to be contacted again.  
 
6 month prospective evaluation 
All 267 eligible study subjects in 2009 were contacted by letter (with a reminder after 
two weeks if they failed to respond) inviting them to participate in a 6 month 
prospective healthcare evaluation survey (Reference 2003RH06 119-09-03).  A total of 
141 consented to participate.  Resource use and expenditure data were gathered at 
baseline (namely, at the start of this study), 3 and 6 months by self-completion of the 
same postal questionnaire used in 1999.  
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As in our previous study, [5] study participants were provided with
 
a memory aid in the 
form of a diary to record their
 
resource use and expenditure over the 3-month follow-up 
intervals.
 
Completion of the diary was optional and intended for
 the participants’ 
personal use only.  
 
The NOAR database holds information on socio-demographic
 
data including age, sex, 
smoking status, social class and ethnic group; social class was assigned using the 
Registrar General's system Office of Population Censuses and Surveys, 1991,[9] based 
on the occupation of the individual. Other clinical, laboratory and radiographic data 
recorded in the NOAR database include the 28-joint disease activity score (DAS 28), 
Health Assessment Questionnaire (HAQ),  C-reactive protein (CRP), rheumatoid factor 
and/or cyclic citrullinated peptide antibody (anti-CCP) and presence of erosions on X-
rays. Details on disease-modifying anti-rheumatic drug (DMARD) use were 
documented at each patient review.  
 
Analytical approach (cost calculations) 
Unit costs were applied to the resource-use data using data from the Personal Social 
Services Research Unit 2009 (PSSRU) and for medications, the British National 
Formulary (BNF) 2009 was used.[10]   Medications relating to IP treatment, including 
analgesics, DMARDs and bone-strengthening treatments were costed individually using 
the BNF and based on the number of prescriptions, assuming that each prescription was 
for one month (from the data available). With regards to the biologics, only etanercept 
and adalimumab were prescribed in this study population.  The BNF (2009) reports the 
price of both anti-TNFs as £89.38 per 25-mg prefilled syringe for etanercept (standard 
dose of 25mg twice weekly or 50mg once weekly)  and £357.50 per 40-mg prefilled 
syringe for adalimumab (standard dose 40mg on alternate weeks).  
 
The direct health costs per participant over 6 months was estimated following the same 
methodology as reported by Cooper et al.,[5] in the earlier study. We combined resource 
use data with the unit costs using the following general costing formula:[5]  
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑠𝑡 = ∑ ∑(𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦)𝑖𝑗
𝑚
𝑗=1
𝑛
𝑖=1
 ×  (𝑢𝑛𝑖𝑡 𝑐𝑜𝑠𝑡)𝑗 
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where i is the ith individual (i=1..…….n) and  j is the jth service received (j=1……..m) 
(i.e., inpatient and outpatient care, and different second line drugs).  
 
All costs were inflated to 2013 prices (Bank of England inflation calculator).[11] A 
table of unit costs is available online, where all costs are expressed in 2013 UK sterling.  
 
Separate cost categories were then defined, including: hospital, community and 
treatment costs.  Health care costs are typically right skewed[12] due to the small 
number of patients reporting high treatment costs compared with the population as a 
whole. For interpretation of our results, we report the following descriptive statistics for 
each variable: 
1. Number and proportion (%) of participants using specific services. 
2. Mean, standard deviation and the 95% confidence intervals for costs calculated 
on all resource use. 
The individual costs per patient were calculated for the 6 month period, using STATA 
11 and Microsoft Excel.  
 
Results 
 
Patient sample description 
Of the 141 responders who consented to participate, 101 (72%) returned complete data 
at baseline, 3 and 6 months.  Their baseline characteristics are shown in Table 1. Their 
mean age was 49.8 years (SD 12.0); 63% were female and mean disease duration was 
14 years (SD 2.1, median 13.6, IQR 12.6-15.4).  The baseline characteristics in the 
present study were broadly similar to the baseline characteristics of the subjects 
originally included in the 1999 study, the only difference related to their longer disease 
duration.  The patients in the current study had comparable age with the 1999 cohort 
(mean 50 years vs 52 years respectively) similar disease duration at entry (47 vs 51 
months), gender (female 64% vs 62%) and HAQ at entry (median 0.63 vs 0.75).  
Compared to the 1999 study, as would be expected with longer follow up, a greater 
proportion of patients (63% compared to 50%) had been classified by ACR criteria[13] 
as having RA.  Biologic drugs were used by 14 patients (14%) during the 6-month study 
period. As expected, those who developed established RA during follow up  showed 
higher DAS28, CRP and HAQ at baseline than the group overall. 
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Costs of disease 
The total direct cost incurred by all IP (n=101) patients was £128,903 over the 6 month 
study period, with a mean cost of £1,276 (95% CI £856-£1696) (£1,493 inflated for 
2013 prices) per patient and a Total Annual Direct cost (TAD) of £2,556.00 (£2,991, 
inflated for 2013 prices).  Medications and biologic drugs accounted for the largest 
proportion of the total health care cost (54%), followed by hospital outpatient visits and 
day care admission (31%).  Inpatient hospital stay for orthopaedic intervention was 
required for two patients in the 6-month follow-up interval. Inpatient admissions 
accounted for 4% of the total cost in this sample.  Outpatient hospital visits (including 
both consultations with doctors and nurses) accounted for 19% of the cost for IP and use 
of day unit facilities accounted for 12%. Community visits, including visits to the 
General Practitioner (GP), GP nurse and community physiotherapy, and occupational 
therapy accounted for 11% of the total cost of IP. 
 
In those who developed RA (n=64) the mean total cost per patient over the 6 month 
period was £1,715 (95% CI £1,105-£2,326), TAD cost £3,430 (£2,007 and £4,014 
respectively inflated for 2013 prices).  Use of biologic drugs accounted for 51% of the 
total direct costs, despite only 14% of the cohort having been prescribed these drugs.   
Other IP-related medications accounted for an additional 6% of the cost.   
 
The costs of all IP patients and also the disaggregated costs for the RA group over the 6 
month study period are reported in Table 2 displaying the 50
th
 percentile (median), 75
th
 
percentile and maximum values to allow for a clear representation of the distribution of 
the data.  
 
Discussion  
 
The previous literature on the economic impact of IP and RA has focussed on the short-
term direct medical costs.  This is the first study to capture the associated long-term 
direct medical costs, in an era where emphasis is placed on the use of earlier and more 
intensive treatments.  There has been a shift from a limited number of drugs with slow 
acting and/or marginal effects to use of more potent drugs such as the biologics, when 
first line synthetic DMARDs fail to control disease. The clinical effectiveness and 
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benefits of biologic agents on both short-term and longer-term outcomes of disease is 
now well-established.  However, they do represent the most expensive type of 
medication for IP and this restricts their use in the UK since their availability in 2002.  
This study has shown that up to 15 years after the onset of IP, biologic agents accounted 
for over 50% of the total cost associated with disease. 
 
However, like-for-like comparison with our earlier 1999 study for individual resource 
use is not possible because of methodological differences, individual cost components 
being grouped differently and the focus of the study being on both direct and indirect 
costs.  The 1999 study was not designed with long term follow up of health economic 
outcomes in mind, and a group of patients were not consented for further questionnaire 
contact.  While the present and original cohorts were broadly similar in their baseline 
characteristics, the possibility of selective difference influencing the comparison cannot 
be excluded fully. Nevertheless, we believe valid comparisons of broad trends for the 
most notable differences over time are possible.   In the 1999 study a greater proportion 
of the total 6-month health-service costs (42%) were attributable to a minority of 
individuals who incurred an in-patient stay or day-care visit (6%).  These ‘high cost’ 
individuals represented 10% of the cohort and incurred 50% of the total 6 month costs 
(both health and non-health service).  
 
In the current study, outpatient visits and day care admission accounted for just under 
one third of the cost (31%), whereas inpatient admission was only reflected by 4% of 
the cost over the 6 month period.  The in-patient admissions were for orthopaedic-
related interventions. The observed shift from inpatient to outpatient care could be due 
to better management and more intensive treatment of patients in the outpatient setting 
and could relate to the use of biologic agents.  However, we can only speculate on this 
observation which could also simply be a reflection of the changing approach to 
delivering care to patients with IP in the UK. 
 
The mean direct (health service) medical cost per patient over the 6-month period in this 
study was £1,493 for all IP (inflated for 2013 prices). This compared with £582 (95% 
CI £355-£964) inflated to 2013 prices (£385; 95% CI £235-£638 in 1999 prices) per 
patient with IP ten years earlier in their disease.[5]  There has, therefore, been an 
obvious increase in costs, with the use of biologics being a major contributor.  
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Whilst direct comparisons between studies based on differing healthcare systems using 
different economic evaluations is not possible, it is of interest that our figures are 
comparable to those reported in studies from the USA, Canada and Europe, accounting 
for inflation.[14,15] In a prospective longitudinal study of costs incurred by RA patients 
in Saskatoon and Montreal [14], annual direct costs increased by almost 20% in the late 
1980s compared to the early 1990s. Institutional stays and medications made up at least 
80% of total direct costs, the former being more frequent in the older and more disabled 
as one would expect. In this study that was published in 1997, the authors concluded 
that measures to reduce long-term disability by using earlier and more aggressive 
intervention have the potential to produce considerable cost savings. However, it was 
unknown then which strategies would have the greatest effect on outcome and the 
optimal allocation of resources.  Direct comparison of the results with other studies can 
be challenging and may be inappropriate, due to differences in health systems, 
population characteristics e.g. age, gender, disease severity and duration[1] as well as 
methodological differences e.g. different cost components, unit costs, etc. Therefore, 
generalisation of the results to a wider geographical area and other healthcare systems is 
not possible and is an unavoidable limitation of the study.   
 
The study is limited by the fact that information on the indirect health care costs (such 
as productivity losses to the individual, family, employer and society as a result of 
illness) was not sufficiently and robustly collected, and we anticipate that our results 
will have underestimated the full societal cost of the disease.   Details on investigational 
costs e.g. for imaging and blood tests were not included, which could result in under-
estimation of costs.  However, our aim was to provide a description of the direct 
medical costs in this cohort of patients with a view to assessing the changing cost of 
disease and healthcare utilization group over time.  By adopting similar methodology to 
our earlier study we provide an overall assessment of their inpatient and outpatient care.  
Finally, the use of self-reported questionnaires to collect information on resource and 
drug use and costs is a limitation of the study.  However, we tried to minimise the risk 
of patient recall bias, by providing study participants with a memory aid in the form of a 
diary in which to record their resource use and expenditure over the two 3-month 
follow-up intervals. 
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One of the key issues surrounding the use of biologic agents in IP is whether the long 
term cost of the disease will be reduced by the introduction of more effective treatments 
earlier in the disease. Comparative data will be needed from later cohorts to provide 
insight into this.  However the present study has shown that biologic use among this 
cohort currently dominates the direct cost of the long term management of IP when 
compared to all other aspects of direct medical care.  
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Table 1.  Patient characteristics by RA status at the time of recruitment into the study. 
 IP  
N=101 
RA group* 
N=64 
Age at onset, years (mean. s.d) 49.8 (12.0) 51.1 (11.5) 
Disease duration, years (mean, s.d.) 14(2.1) 14.4 (2.2) 
Gender, female 64 (63%) 49 (77%) 
HAQ score (median, range) 0.63 (0.13 – 1.19) 0.88 (0.38 – 1.38) 
DAS28crp(3) (mean, s.d) 3.6 (1.4) 4.2 (1.1) 
CRP, mg/L(median, range) 7 (0 – 15) 11 (3 – 23) 
Swollen joint count, 28 joints (median, range) 3 (1 – 8) 5.5 (2 – 11) 
Tender joint count, 28 joints (median, range) 4 (1 – 6) 5 (2 – 9) 
RF, positive 32 (34%) 28 (45%) 
Anti-CCP, positive 27 (31%) 25 (44%) 
Erosions, yes 10 (51%) 9 (69%) 
On DMARDs 36 (36%) 24 (38%) 
N = number of patients with available data. Mean, standard deviation (s.d.) reported for all normally-
distributed variables; median and inter-quartile range (IQR) reported for non-normally distributed 
variables. Percentages of total number shown in parentheses. 
*classified by ACR criteria applied at 5 years after disease onset 
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Table 2. Disaggregated costs for IP and the RA sub-group. 
 
 
 
GP=General Practitioner; NP=Nurse practitioner. 50
th
 PL = 50th percentile (median); 75
th
 PL= 75
th
 
percentile; max=maximum value. All costs are reported in £ sterling and for the price year 2013.  % 
indicates the percentage usage of the indicated resource service; s.d.=standard deviation. In view of the 
short study period of two 3-month intervals, mean resource use per patient was mostly once.
 
IP (n=101) RA group (n=64) 
Cost (£) Cost (£) 
Resource use N using 
(%) 
50
th
 PL, 75
th 
PL, 
max
 
s.d. 95% CI N using 
(%) 
50
th
 PL, 75
th
 
PL, max s.d. 95% CI 
GP nurse visits 55 (54) 33,169,950 193.36 142.09-246.71 43 (67) 84,203,950 189.98 139.65-256.61 
GP nurse calls 14 (14) 0,0,77 24.19 20.26-44.12 10 (16) 0,0,77 22.75 18.49-51.03 
NP visits 40 (40) 0,50,754 170.19 110.39 - 219.26 34 (53) 50,100.65,754 179.45 98.74-223.96 
NP calls 16 (16) 0,0,38 11.02 16.65-28.40 13 (20) 0,0,38 10.70 16.30-29.24 
GP visit 47 (46) 0,72,544 96.57 36.28-55.01 33 (52) 36,72,544 16.03 56.40-121.71 
GP call 15 (15) 0,0,400 96.28 31.19-137.82 11 (17) 0,0,400 109.56 5.24-152.45 
Hospital doctor visits 56 (55) 143,294,1917 294.94 250.20-291.12 41 (64) 147,294,884 209.82 232.32-364.78 
Hospital doctor calls 13 (13) 0,0,333 87.63 18.89-124.80 11 (17) 0,0,333 93.82 3.68-129.74 
Day care stay 9 (9) 0,0,5227 1627.51 740.56-3242.36 7 (11) 0,0,5227 1693.48 780.73-3913.14 
Inpatient stay 2 (2) 0,0,3073 0 3073.63-3073.63 2 (3) 0,0,3073.63 0 3073.63-3073.63 
Physiotherapy 16 (16) 0,0,252 55.90 66.99-126.57 10 (16) 0,0,126 29.97 63.88-106.76 
Occupational Therapy 
13 (13) 0,0,126 35.05 51.74-94.11 11 (17) 0,0,126 37.63 46.57-97.11 
Total medication use 81 (80) 30,845,103 190.11 87.89-171.96 56 (88) 39,121,845 191.96 83.85-163.25 
Total cost biologics 14 (14) 0,0,5021 0 5021.42-5021.42 13 (20) 0,0,5021 0 5021.42-5021.42 
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Supplementary material uploaded online for unit costs and expenditure questionnaires. 
